All Professionals
Overview
Xingyan Zhou is an associate in the Paul Hastings Corporate Department and is based in the firm’s Beijing office. Her practice focuses on public offerings in Hong Kong, mergers and acquisitions, and private equity transactions.
Xingyan passed the bar examination in China in 2023 but does not hold a current practicing certificate in China. She is fluent in English and Mandarin.
Education
- University of International Business and Economics, LL.B. 2023
Representations
- Shuangdeng Group, a leading company in energy storage business for big-data and telecommunication industries, on its approximately US$110 million global offering and IPO on the Main Board of the Hong Kong Stock Exchange.
- Zhejiang Taimei Medical Technology Co., Ltd., a digital solution provider for life sciences R&D and commercialization in China, on its approximately US$50 million global offering and IPO on the Main Board of the Hong Kong Stock Exchange.
- Laopu Gold Co., Ltd., a Chinese heritage gold jewelry brand accredited by the China Gold Association, on its approximately US$116 million global offering and IPO on the Main Board of the Hong Kong Stock Exchange.
- Chenghe Acquisition II, a special acquisition company (SPAC), on its approximately US$86.25 million initial public offering on the New York Stock Exchange.
- Adlai Nortye Ltd., a global clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies, on its approximately US$97.5 million initial public offering on the Nasdaq Stock Market.
- CMB International as sole sponsor, and other underwriters, on the approximately US$115 million global offering and listing of Bayzed Health Group Inc., an oncology healthcare group that principally engages in the investment in and provision of medical related services in China, on the Main Board of the Hong Kong Stock Exchange.
Matters may have been completed before joining Paul Hastings.